You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,790,518


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,790,518
Title:Furin-knockdown and GM-CSF-augmented (FANG) cancer vaccine
Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-.beta. through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to segment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.
Inventor(s): Nemunaitis; John J. (Cedar Hill, TX), Senzer; Neil (Dallas, TX), Maples; Phillip B. (Pilot Point, TX), Rao; Donald (Dallas, TX)
Assignee: GRADALIS, INC. (Dallas, TX)
Application Number:14/815,721
Patent Claims:1. A method of treating a cancer in an individual in need thereof comprising: a. transfecting an autologous tumor cell from the individual with an expression vector comprising: i. a first insert comprising a nucleic acid sequence encoding a Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sequence; and ii. a second insert comprising a sequence according to SEQ ID NO: 2; and b. administering the transfected tumor cell to the individual.

2. The method of claim 1, wherein the GM-CSF is a human GM-CSF sequence.

3. The method of claim 1, wherein the expression vector further comprises a promoter.

4. The method of claim 3, wherein the promoter is a cytomegalovirus (CMV) mammalian promoter.

5. The method of claim 4, wherein the expression vector further comprises a CMV enhancer sequence and a CMV intron sequence.

6. The method of claim 3, wherein the first insert and the second insert are operably linked to the promoter.

7. The method of claim 1, wherein the expression vector further comprises a nucleic acid sequence encoding a picornaviral 2A ribosomal skip peptide between the first and the second nucleic acid inserts.

8. The method of claim 1, wherein the cancer is a melanoma, non-small cell lung cancer (NSCLC), gall bladder cancer, colorectal cancer, breast cancer, ovarian cancer, liver cancer, liver cancer metastases, or Ewing's sarcoma.

9. The method of claim 1, wherein the transfected tumor cell is administered to the individual as a dose of about 1.times.10.sup.7 cells to about 5.times.10.sup.7 cells.

10. The method of claim 9, wherein the transfected tumor cells are administered to the individual once a month.

11. The method of claim 1, wherein the transfected tumor cell is administered to the individual by intradermal injection.

Details for Patent 9,790,518

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2029-12-23
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2029-12-23
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2029-12-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.